HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection

Histopathology

Volumn 54, Issue 6, 2009, Pages 677-687

  Li, Yu ^a   Xu, Jing ^a   Chen, Li ^b   Zhong, Wei De ^d   Zhang, Zheng ^a   Mi, Li ^a   Zhang, Yang ^a   Liao, Cheng Gong ^a   Bian, Hui Jie ^a   Jiang, Jian Li ^a   Yang, Xiang Min ^a   Li, Xiao Yan ^c   Fan, Chun Mei ^c   Zhu, Ping ^c   Fu, Li ^a   Chen, Zhi Nan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer associated biomarker; CD147; Immunohistochemistry; Prognosis; Tissue array

Indexed keywords

CD147 ANTIGEN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOMA; CONTROLLED STUDY; FEMALE; FETUS (ANATOMY); HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA; TISSUE MICROARRAY; TUMOR RECURRENCE;

ANTIGENS, CD147; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 65349118157     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03280.x     Document Type: Article

References (50)

1. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat. Biotechnol. 2006 24 905 908. (Pubitemid 44215377)
2. Bast RC Jr., Lilja H, Urban N et al. Translational crossroads for biomarkers. Clin. Cancer Res. 2005 11 6103 6108. (Pubitemid 41262935)
3. Basil CF, Zhao YD, Zavaglia K et al. Common cancer biomarkers. Cancer Res. 2006 66 2953 2961.
4. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998 84 101 108. (Pubitemid 28275335)
5. Farghaly SA. Tumor markers in gynecologic cancer. Gynecol. Obstet. Invest. 1992 34 65 72.
6. Chen ZN, Liu YF. Monoclonal antibody HAb18 to human hepatoma. Monoclonal antibodies 1990 8 11.
7. Chen ZN, Yang Z, Mi L, Jiang JL, Guo XN. Analysis on the structure and function of hepatoma transfer-associated factor HAb18G (in Chinese). J. Mol. Cell. Immunol. 1999 15 34.
8. Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC. The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J. Biol. Chem. 2001 276 46870 46877. (Pubitemid 37373056)
9. Chen ZN, Shang P, Li Y, Qian AR, Zhu P, Xing JL, inventors NTD patent & trademark agency Ltd., Beijing office, assignee. HAb18G/CD147, its agonist and application. Chinese patent ZL01131735.3, 2001 Sep 28; PCT international patent WO02/094875. 27 May 2002.
10. Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr. Top. Dev. Biol. 2003 54 371 389. (Pubitemid 137639474)
11. Yu XL, Jiang JL, Li L, Feng Q, Xu J, Chen ZN. The glycosylation characteristic of hepatoma-associated antigen HAb18G/CD147 in human hepatoma cells. Int. J. Biochem. Cell Biol. 2006 38 1939 1945. (Pubitemid 44425251)
12. Yu XL, Hu T, Du JM et al. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J. Biol. Chem. 2008 283 18056 18065.
13. Ku XM, Liao CG, Li Y et al. Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma-associated antigen HAb18G/CD147. Scand. J. Immunol. 2007 65 435 443. (Pubitemid 46632549)
14. 131I) metuximab injection: clinical phase I/II trials. Int. J. Radiat. Oncol. 2006 65 435 444. (Pubitemid 43183569)
15. Huang Y, Jiang J, Dou K, Chen Z. HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Eur. J. Cell Biol. 2005 84 59 73.
16. Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN. Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J. Gastroenterol. 2003 9 2174 2177. (Pubitemid 37321439)
17. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int. J. Cancer 2006 118 879 888. (Pubitemid 43157663)
18. Jiang JL, Chan HC, Zhou Q et al. HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell. Mol. Life Sci. 2004 61 2083 2091. (Pubitemid 39149897)
19. Xu J, Xu HY, Zhang Q et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol. Cancer Res. 2007 5 605 614. (Pubitemid 46985049)
20. Xu J, Shen ZY, Chen XG et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007 45 269 276. (Pubitemid 46374583)
21. Zhang Q, Chen XG, Zhou J et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol. Ther. 2006 5 808 814.
22. Zhang Q, Zhou J, Ku XM et al. Expression of CD147 as a significant unfavorable prognostic factor in hepatocellular carcinoma. Eur. J. Cancer Prev. 2007 16 196 202. (Pubitemid 46597423)
23. Sameshima T, Nabeshima K, Toole BP et al. Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int. J. Cancer 2000 88 21 27. (Pubitemid 30129521)
24. Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R, Gladson CL. Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 2003 113 1406 1410. (Pubitemid 36944687)
25. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin. Exp. Metastasis 2003 20 161 169. (Pubitemid 36403281)
26. Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int. J. Urol. 2006 13 573 580. (Pubitemid 43760423)
27. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am. J. Pathol. 1997 151 665 670. (Pubitemid 27385597)
28. Reimers N, Zafrakas K, Assmann V et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 2004 10 3422 3428. (Pubitemid 38685448)
29. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003 327 794 798. (Pubitemid 37211176)
30. Tavassoli FA, Devilee P. Pathology and genetics, tumours of the breast and female genital organs. In Tavassoli FA, Devilee P eds. Tumors of the Brest and Female Genital Organs. WHO classification of tumours. Lyon : IARC Press, 2003 19 110.
31. Ugrinska A, Bombardieri E, Stokkel MP, Crippa F, Pauwels EK. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q. J. Nucl. Med. 2002 46 88 104.
32. The JG, McKenzie IF. Monoclonal antibodies to carcino-embryonic antigen. Immunol. Cell Biol. 1990 68 263 268. (Pubitemid 20354512)
33. Taylor OM, Cooper EH, Benson EA, McMahon MJ. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas. Eur. J. Surg. Oncol. 1992 18 508 513.
34. Harrison JD, Stanley J, Morris DL. CEA and CA 19.9 in gastric juice and serum: an aid in the diagnosis of gastric carcinoma? Eur. J. Surg. Oncol. 1989 15 253 257. (Pubitemid 19190120)
35. Barlesi F, Gimenez C, Torre JP et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir. Med. 2004 98 357 362. (Pubitemid 38443696)
36. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int. J. Biol. Markers 1989 4 207 214. (Pubitemid 20116175)
37. De Potter CR, Beghin C, Praet MM, Pauwels CF, Roels HJ. CEA and HMFG in hyperplastic and malignant lesions of the breast. Pathol. Res. Pract. 1988 183 271 276. (Pubitemid 18155869)
38. Genega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod. Pathol. 2000 13 1186 1191.
39. Cherchi PL, Marras V, Capobianco G et al. Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results. Eur. J. Gynaecol. Oncol. 2001 22 433 435. (Pubitemid 34160729)
40. Al-azawi D, Kelly G, Myers E et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006 5 220 226. (Pubitemid 44509018)
41. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 2006 24 252 258. (Pubitemid 46622054)
42. Abe Y, Odagiri E, Jibiki K, Demura R, Demura H. A study of the clinical usefulness of the CA15-3 radioimmunoassay kit. Gan. No. Rinsho. 1988 34 1672 1676.
43. Gadducci A, Ferdeghini M, Prontera C et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol. Oncol. 1992 44 147 154.
44. Zimmerman RL, Burke M, Young NA, Solomides CC, Bibbo M. Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 2002 96 53 57. (Pubitemid 34194321)
45. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 2006 12 1175 1181.
46. Bast RC Jr., Badgwell D, Lu Z et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 2005 15 274 281.
47. Chen ZN. Significance and application of anti-malignant hepatoma MAb HAb18 in radioimmunal diagnosis of human hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 1992 14 9 12.
48. Li M, Zhai Q, Bharadwaj U et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006 106 2284 2294. (Pubitemid 43673252)
49. Vigneswaran N, Beckers S, Waigel S et al. Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp. Mol. Pathol. 2006 80 147 159. (Pubitemid 43295534)
50. Riethdorf S, Reimers N, Assmann V et al. High incidence of EMMPRIN expression in human tumors. Int. J. Cancer 2006 119 1800 1810. (Pubitemid 44356836)